Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.58 |
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29415502 | 1.00 | IDO1 (0.58) | IDO1HTR2ARETTSHRADRA2A | |
| SCHEMBL40422 | 1.00 | IDO1 (0.58) | IDO1HTR2ARETTSHRADRA2A | |
| SCHEMBL14543304 | 1.00 | IDO1 (0.58) | IDO1HTR2ARETTSHRADRA2A | |
| SCHEMBL10774751 | 1.00 | IDO1 (0.58) | IDO1HTR2ARETTSHRADRA2A | |
| SCHEMBL44600 | 1.00 | IDO1 (0.58) | IDO1HTR2ARETTSHRADRA2A | |
| SCHEMBL469047 | 1.00 | IDO1 (0.58) | IDO1HTR2ARETTSHRADRA2A | |
| Bromide SCHEMBL3727459 | 0.98 | IDO1 (0.56) | IDO1HTR2ARETADRA2AADRA1A | |
| Methane SCHEMBL9503230 | 0.98 | IDO1 (0.56) | IDO1HTR2ARETADRA2AADRA1A | |
| Hydrochloric Acid SCHEMBL7424398 | 0.98 | IDO1 (0.59) | IDO1HTR2ARET | |
| Hydrochloric Acid SCHEMBL29757860 | 0.98 | IDO1 (0.59) | IDO1HTR2ARET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312363-B2 | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-p53 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-05-27 | — | — | US | disclosed |
| US-20240109913-A1 | NEW SPIRO[3H-INDOLE-3,2'-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2024-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12312363-B2 | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-p53 inhibitors | TP53, MDM2, FOXM1 | IDO1 13/4885HTR2A 486/4885RET 762/4885 |
| US-20240109913-A1 | NEW SPIRO[3H-INDOLE-3,2'-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS | TP53, MDM2, FOXM1 | IDO1 20/4885HTR2A 451/4885RET 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.